title: Decreased expression of serum miR-424 correlates with poor prognosis of patients with hepatocellular carcinoma.
abstract: BACKGROUND
  MicroRNAs (miRNAs) play important roles in many important cellular processes and deregulation of miRNAs is linked to many human diseases including cancer. Although miR-424 has been demonstrated to inhibit progression of hepatocellular carcinoma (HCC), its expression level in serum samples and the potential clinical values remain unknown.
  
  
  METHODS
  The expression level of miR-424 in the serum clinical samples from HCC patients and healthy volunteers were determined by qRT-PCR. Then the association of serum miR-424 expression level with various important clinicopathological parameters and survival rates was evaluated. Multivariate Cox regression analysis was used to identify the independent risk factors for HCC.
  
  
  RESULTS
  The expression level of serum miR-424 was significantly decreased in patients with HCC compared with the healthy volunteers (P<0.01). Reduced expression of serum miR-424 was associated with serum AFP (P=0.048), vein invasion (P=0.006) and TNM stage (P=0.003). In addition, survival analysis showed that HCC patients with lower serum miR-424 expression suffered poorer overall survival (P=0.018) and disease free survival (P=0.008). Moreover, serum miR-424 was demonstrated to be an independent risk factor for HCC.
  
  
  CONCLUSIONS
  Our findings provide the compelling evidence that the decreased expression of serum miR-424 may serve as a novel biomarker to predict the unfavorable prognosis of HCC patients.
authors.affiliation: Department of Ultrasound, The First Affiliated Hospital of Shantou University Medical College Shantou 515041, Guangdong Province, China.
authors.forename: Huaiqi
authors.initials: H
authors.lastname: Yao
authors.affiliation: Department of Ultrasound, The First Affiliated Hospital of Shantou University Medical College Shantou 515041, Guangdong Province, China.
authors.forename: Xuanzhi
authors.initials: X
authors.lastname: Liu
authors.affiliation: Department of Gastroenterology, The First Affiliated Hospital of Shantou University Medical College Shantou 515041, Guangdong Province, China.
authors.forename: Suzuan
authors.initials: S
authors.lastname: Chen
authors.affiliation: Department of Intervention, The First Affiliated Hospital of Shantou University Medical College Shantou 515041, Guangdong Province, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Xia
authors.affiliation: Department of Gastroenterology, The First Affiliated Hospital of Shantou University Medical College Shantou 515041, Guangdong Province, China.
authors.forename: Xiaojun
authors.initials: X
authors.lastname: Chen
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood* / Q000235:genetics; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000401:mortality / Q000473:pathology*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000097:blood / Q000401:mortality / Q000473:pathology*; D008297:Male; D035683:MicroRNAs / Q000097:blood*; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D014408:Biomarkers, Tumor; C554214:MIRN424 microrna, human; D035683:MicroRNAs
keywords: Hepatocellular carcinoma; miR-424; prognosis; serum
references.citation: Nat Rev Genet. 2004 Jul;5(7):522-31
references.pmid: 15211354
references.citation: Biochem Biophys Res Commun. 2015 Aug 14;464(1):161-7
references.pmid: 26116538
references.citation: J Dermatol. 2014 May;41(5):382-5
references.pmid: 24628460
references.citation: Oncol Rep. 2015 May;33(5):2354-60
references.pmid: 25708247
references.citation: Nat Clin Pract Oncol. 2007 Jul;4(7):424-32
references.pmid: 17597707
references.citation: Med Oncol. 2012 Jun;29(2):919-27
references.pmid: 21390519
references.citation: Oncotarget. 2015 Sep 29;6(29):27736-50
references.pmid: 26315541
references.citation: Tumour Biol. 2014 Nov;35(11):10731-6
references.pmid: 25073511
references.citation: Biol Reprod. 2013 Aug;89(2):25
references.pmid: 23803556
references.citation: Cancer Lett. 2015 May 1;360(2):245-56
references.pmid: 25697481
references.citation: Sci Rep. 2014;4:6248
references.pmid: 25175916
references.citation: Nat Med. 2013 Jan;19(1):74-82
references.pmid: 23263626
references.citation: PLoS One. 2014;9(3):e91661
references.pmid: 24675898
references.citation: Oncology. 2011;80(3-4):167-74
references.pmid: 21701230
references.citation: Pathol Oncol Res. 2013 Oct;19(4):739-48
references.pmid: 23653113
references.citation: Oncotarget. 2015 Sep 15;6(27):24119-31
references.pmid: 26090723
references.citation: Cell Stem Cell. 2010 Jul 2;7(1):36-41
references.pmid: 20621048
references.citation: Int J Cancer. 2010 Dec 15;127(12):2893-917
references.pmid: 21351269
references.citation: Cell Cycle. 2008 Oct;7(20):3143-8
references.pmid: 18843198
references.citation: J Dig Dis. 2010 Feb;11(1):50-4
references.pmid: 20132431
references.citation: World J Hepatol. 2015 May 28;7(9):1157-67
references.pmid: 26019732
references.citation: Cardiovasc Res. 2013 Jun 1;98(3):458-68
references.pmid: 23447642
references.citation: Arch Biochem Biophys. 2015 Jan 15;566:49-57
references.pmid: 25524739
references.citation: Annu Rev Med. 2009;60:167-79
references.pmid: 19630570